Revolution Medicines, Inc.
RVMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.69 | -0.29 | -0.31 | -0.19 |
| FCF Yield | -7.74% | -11.04% | -12.25% | -8.39% |
| EV / EBITDA | -10.23 | -5.52 | -7.33 | -9.96 |
| Quality | ||||
| ROIC | -28.61% | -25.10% | -34.07% | -27.49% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.93 | 0.80 | 0.90 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -26.69% | -6.28% | -16.26% |
| Free Cash Flow Growth | -58.45% | -52.33% | -53.03% | -49.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 1.27 | 0.39 | 0.23 |
| Interest Coverage | 0.00 | -1,607.87 | 0.00 | -15,667.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 39.53 | 48.21 | 73.63 |